Humacyte (NASDAQ:HUMA) Shares Up 10% – Still a Buy?

Shares of Humacyte, Inc. (NASDAQ:HUMA) traded up 10% on Wednesday . The stock traded as high as $4.54 and last traded at $4.53. 2,101,798 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 3,351,322 shares. The stock had previously closed at $4.12.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on HUMA shares. Benchmark upped their price target on Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, December 23rd. HC Wainwright restated a “buy” rating and set a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a research report on Friday, December 20th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Monday. TD Cowen reissued a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Finally, Piper Sandler set a $6.00 price objective on Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Humacyte has a consensus rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Down 1.6 %

The business’s fifty day moving average is $4.60 and its 200 day moving average is $5.66. The stock has a market cap of $555.04 million, a PE ratio of -3.29 and a beta of 1.32.

Insider Transactions at Humacyte

In related news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Laura E. Niklason sold 811,172 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the sale, the chief executive officer now owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. The trade was a 25.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock valued at $6,606,799 in the last quarter. 11.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Humacyte

Hedge funds have recently added to or reduced their stakes in the business. Brookstone Capital Management acquired a new stake in shares of Humacyte in the fourth quarter valued at approximately $56,000. ACT Wealth Management LLC purchased a new position in Humacyte during the fourth quarter worth $57,000. Concurrent Investment Advisors LLC acquired a new position in shares of Humacyte in the third quarter worth $75,000. FORA Capital LLC purchased a new stake in shares of Humacyte in the third quarter valued at $96,000. Finally, Profund Advisors LLC acquired a new stake in shares of Humacyte during the second quarter valued at $97,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.